Eli Lilly's blockbuster obesity drug Mounjaro became India's top-selling drug by value for the month of October with sales hitting ₹1 billion ($11.38 million), research firm Pharmarack said on Friday, reported Reuters. Mounjaro's rapid rise is a testament to the growing demand for effective diabetes and obesity treatments in India, where around 101 million people – 11.4 percent of the country's population – live with diabetes, as per a 2023 Lancet study. Butwhat is the drug and what are the side impacts? Is it even worth it? #mounjaro #weightloss #nutrition #fitness #workout #obesity #overweight #bloodpressure #hypertension #donaldtrump #economy #india #drugs #drug #medicine #lifestyle #lifestyledisease #diabetes #sugar #narendramodi #abhinavtrivedi #sanamarawaha